About us

90 years of experience brought together to lead the medicinal cannabis future

Linneo Health is a global leader in the research, EU-GMP certified manufacture and supply of medicinal cannabis flowers, extracts and products to pharmaceutical partners developing innovative cannabis-based therapies for patients in need. As the world’s only vertically integrated medicinal cannabis supplier, supported by 90 years of unparalleled heritage and experience in the production of strictly regulated pharmaceutical products, Linneo Health is setting the benchmark for quality in research, cultivation and supply of medicinal cannabis to drive innovation and excellence in the field.

Linneo’s European operations center in Southern Spain is optimally positioned to address the needs of its customers through every stage of product development, regulation and handling. Driven by the belief that people around the world deserve to be treated with cannabis medicine of the highest standard, Linneo’s expertise provides a clear reference for today’s industry, alongside significant expansion capabilities to support the development of tomorrow’s solutions in a rapidly evolving market.

Linneo Health takes 90 years of experience in the agricultural and industrial production of highly regulated narcotics and puts them at the service of the cannabis industry. We work with the highest production standards, and this clear focus on the quality of what we do has been accredited by the EU-GMP and GACP certifications to our production process.

In order to accomplish our ambitious expansion plan, we currently have 40,000 m2 of land devoted to the production of cannabis dried flowers. In addition, we have the industrial capacity to process over 12,000 tonnes of biomass per year for the production of extracts and active ingredients derived from cannabis. These capabilities, added to our expertise, position Linneo Health as one of the market leaders and a clear reference in the industry.

 
Our story

Linneo Health was built on the principle of providing the highest quality medicinal cannabis products to improve lives.

October 2016

We received authorization for the cultivation of cannabis with medical and scientific purposes from the Spanish Agency for Medicines and Health Devices (AEMPS).

2017

We started construction on our first greenhouse for growing our medicinal cannabis.

June 2019

Our first outdoor growing area was approved, significantly expanding our agricultural capacity and strengthening our robust business model.

September 2019

We received the Good Manufacturing Practices (GMP) quality certificate from the Spanish Agency for Medicines and Health Devices (AEMPS) - the first Spanish cannabis company to receive this certification.

December 2019

Our cultivation area was awarded with the Good Agricultural and Collection Practices (GACP) certificate, which restates our cultivation process as the reference in the medicinal cannabis sector.

2020

We shipped the first commercial products to our client, officially starting our commercial journey.

Satisfactory approval achieved for dossier of irradiated product for Germany.

Launch of first commercial batch in Germany.

Harvest of largest cannabis outdoor crop destined for export.

Completion of dedicated cannabis extraction unit.

April 2021

Our State-of-the-art Quality Control Laboratory became fully operational and received the visit of the Spanish Medicinal Agency for Medicines and Health Devices (AEMPS) for GLP certification.

September 2021

We obtained GMP Certification for our newly built quality control laboratory by the Spanish Medicinal Agency for Medicines and Health Devices (AEMPS) and renewed the existing GMP certification for the current facility, allowing us to continue being a leader in the cannabis sector.

July 2022

We were awarded the maximum grant of €200,000 from the ICEX, Invest in Spain framework, to support our ongoing CANNABI+ project, which aims to develop new cannabis varieties with unique cannabinoid and terpene profiles.

July 2022

We expanded our medicinal cannabis offering to include industrial derivatives, following the issuance of EU-GMP certification for the industrial processing of cannabis derivatives to Alcaliber, by the Spanish Agency of Medicines and Medical Products (AEMPS).

September 2022

Our dried flower facility was awarded the EU-GMP Part I license by the Spanish Agency of Medicines and Medical Products (AEMPS), for the manufacture of intermediates and finished medicinal cannabis products. This new certification greatly extends our existing Part II license for the manufacture of Active Pharmaceutical Ingredients (APIs).

cdtioficial
fondo europeo de desarrollo regional

The commitment, collective effort and high technological component of our R&D activities have allowed us to be awarded with public institutions.
CANNABI+D Project.  IDI-20190621
The objective of the project focuses on the development of the production process of cannabis sativa focused on the stages of maturation and drying of the product This project has been co-financed by the European Regional Development Fund (ERDF), within the Pluriregional Operational Program of Spain 2014-2020.

CDTI Contribution: 205,707.16 €.

Linneo Health, S.L., within the framework of the Invest in Spain Programme, has received support from ICEX and co-financing from the European ERDF fund for the implementation of the CANNABI+ project, OBTAINING NEW CANNABIS VARIETIES WITH HIGH CANNABINOID CONTENT. The aim of the project is to obtain varieties of cannabis with a high content of varina cannabinoids and specific terpene profiles from which the active ingredients can be obtained.

Amount of the aid: 200,000 euros.

Call for proposals 2021. File: 2021/26